Management of Hypertension in Patients with Heart Failure

Introduction to Treatment

The American College of Cardiology recommends adding dihydropyridine calcium channel blockers to the treatment regimen for hypertension in patients with congestive heart failure (CHF) and diastolic dysfunction when blood pressure remains uncontrolled, while nitrates are not recommended for hypertension management but may be useful for symptom relief in selected heart failure patients 1, 2

First-line therapy for hypertension in patients with heart failure includes ACE inhibitors or ARBs, beta-blockers, and diuretics for volume control, as recommended by the American College of Cardiology 2
Beta-blockers are first-line for patients with prior myocardial infarction (MI) or heart failure, and can be combined with dihydropyridine CCBs 1

Dihydropyridine CCBs, such as amlodipine, can be used when hypertension remains uncontrolled despite first-line therapies, and can be safely added to a basic regimen of beta-blocker, ACE inhibitor, and thiazide diuretic when blood pressure remains uncontrolled 1
The American College of Cardiology suggests that dihydropyridine CCBs should be used only after optimizing first-line agents (ACE inhibitors/ARBs, beta-blockers, and diuretics) 2
Amlodipine dosing is 5-10 mg once daily 3
Felodipine is a reasonable alternative for patients with mild LV dysfunction 3
Ranolazine can be considered for persistent angina despite other therapies, with minimal effects on heart rate and blood pressure, and is particularly effective in women with recurrent ischemia 4

Nitrates have not been shown to be effective for managing hypertension, and their primary indication is angina relief, not blood pressure control, according to the American Heart Association 1, 4
Nitrates can be used in combination with hydralazine in selected heart failure patients, primarily causing venodilation, reducing preload and ventricular filling pressures, and may help reduce symptoms of pulmonary and systemic congestion 1
The American College of Cardiology advises against using nitrates with phosphodiesterase inhibitors (e.g., sildenafil) due to the risk of severe hypotension 1, 4
Immediate-release, short-acting nifedipine should be avoided due to increased risk of mortality in coronary artery disease (CAD) patients, risk of abrupt hypotension, and reflex sympathetic activation worsening myocardial ischemia 5, 4

The target blood pressure should be <130/80 mmHg; if ventricular dysfunction is present, consider targeting <120/80 mmHg, as recommended by the American Heart Association 1
Caution is advised when lowering diastolic BP below 60 mmHg, especially in older patients with wide pulse pressures, according to the American College of Cardiology 1
ACE inhibitors/ARBs should be considered for patients with hypertension and LV dysfunction (LVEF <0.40), diabetes mellitus, or chronic kidney disease 4

Evidence for nitrate use specifically in diastolic dysfunction is limited, as noted by the European Society of Cardiology 6
The American College of Cardiology recommends avoiding non-dihydropyridine CCBs (verapamil, diltiazem) in patients with heart failure due to increased risk of worsening heart failure 2
Diltiazem is contraindicated in patients with severe LV dysfunction, pulmonary edema, PR interval >0.24 seconds, and second or third-degree heart block without pacemaker 3, 4
Verapamil is contraindicated in patients with severe LV dysfunction 3
Caution is needed when discontinuing diltiazem in patients with unstable angina 7
The American College of Cardiology recommends long-acting amlodipine as the preferred dihydropyridine calcium channel blocker (CCB) for patients requiring an alternative to nifedipine for treating hypertension and angina, while diltiazem and verapamil are excellent non-dihydropyridine alternatives depending on patient characteristics 3, 5, 4
For patients with mild left ventricular (LV) dysfunction, amlodipine is well-tolerated 3
For patients who need heart rate control, diltiazem is the best option 5
For patients with atrial fibrillation and hypertension, diltiazem is recommended 5
For patients with vasospastic angina, any CCB is appropriate as all have similar coronary vasodilatory effects 5
When transitioning from nifedipine to another agent, ensure adequate dosing and monitoring to maintain blood pressure control and prevent angina recurrence 3, 5, 4